Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311763675> ?p ?o ?g. }
- W4311763675 endingPage "219" @default.
- W4311763675 startingPage "207" @default.
- W4311763675 abstract "Social anxiety disorder (SAD) is associated with scarce functioning and poor quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are currently first-line treatments, side effects are common and affect treatment compliance in approximately 50% of patients. This review aimed to summarize data on the efficacy of unlabeled molecules for SAD treatment.Research in the main psychiatric databases was conducted (PubMed, PsychINFO, and EMBASE-Ovid) to select studies investigating the efficacy of marketed molecules not labeled for SAD treatment.Pregabalin at high doses (450-600 mg/day) appears to be a reliable alternative strategy for SAD treatment. Among the SSRIs not labeled for SAD, citalopram showed the most promising results. Quetiapine, levetiracetam, and other antidepressants/serotonergic agents, such as fluoxetine, duloxetine, monoamine oxidase inhibitors, tricyclics, mirtazapine, atomoxetine, nefazodone, vilazodone, and buspirone, presented negative, limited, or contrasting results. Data on anticonvulsants, olanzapine, tiagabine, and ketamine were positive, but preliminary. The risk/benefit ratio must be considered in the prescription of unlabeled compounds; treatment with pregabalin may be associated with somnolence and dizziness. Future research may contribute to the identification of targeted molecules for the treatment of this disorder." @default.
- W4311763675 created "2022-12-28" @default.
- W4311763675 creator A5005348606 @default.
- W4311763675 creator A5030480720 @default.
- W4311763675 creator A5037660224 @default.
- W4311763675 creator A5058477771 @default.
- W4311763675 creator A5083862525 @default.
- W4311763675 creator A5087822441 @default.
- W4311763675 date "2022-12-22" @default.
- W4311763675 modified "2023-09-27" @default.
- W4311763675 title "New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview" @default.
- W4311763675 cites W1819104005 @default.
- W4311763675 cites W1861509164 @default.
- W4311763675 cites W189463036 @default.
- W4311763675 cites W1967689924 @default.
- W4311763675 cites W1974450862 @default.
- W4311763675 cites W1974899411 @default.
- W4311763675 cites W1978456505 @default.
- W4311763675 cites W1984770623 @default.
- W4311763675 cites W1991261574 @default.
- W4311763675 cites W2001446815 @default.
- W4311763675 cites W2003200137 @default.
- W4311763675 cites W2012788018 @default.
- W4311763675 cites W2015066009 @default.
- W4311763675 cites W2018021892 @default.
- W4311763675 cites W2018996292 @default.
- W4311763675 cites W2020742688 @default.
- W4311763675 cites W2024134830 @default.
- W4311763675 cites W2026151186 @default.
- W4311763675 cites W2028756415 @default.
- W4311763675 cites W2038979554 @default.
- W4311763675 cites W2049702187 @default.
- W4311763675 cites W2052782110 @default.
- W4311763675 cites W2053503259 @default.
- W4311763675 cites W2054080943 @default.
- W4311763675 cites W2058514732 @default.
- W4311763675 cites W2061398723 @default.
- W4311763675 cites W2062617274 @default.
- W4311763675 cites W2081677225 @default.
- W4311763675 cites W2087407577 @default.
- W4311763675 cites W2087717203 @default.
- W4311763675 cites W2088150064 @default.
- W4311763675 cites W2093965134 @default.
- W4311763675 cites W2094366416 @default.
- W4311763675 cites W2099239991 @default.
- W4311763675 cites W2103167441 @default.
- W4311763675 cites W2104772114 @default.
- W4311763675 cites W2117818255 @default.
- W4311763675 cites W2131172148 @default.
- W4311763675 cites W2139376021 @default.
- W4311763675 cites W2150332288 @default.
- W4311763675 cites W2151428461 @default.
- W4311763675 cites W2151914802 @default.
- W4311763675 cites W2152198225 @default.
- W4311763675 cites W2156996273 @default.
- W4311763675 cites W2162163297 @default.
- W4311763675 cites W2165907179 @default.
- W4311763675 cites W2177154801 @default.
- W4311763675 cites W2346114762 @default.
- W4311763675 cites W2491948161 @default.
- W4311763675 cites W2578581505 @default.
- W4311763675 cites W2583101917 @default.
- W4311763675 cites W2599264051 @default.
- W4311763675 cites W2623960085 @default.
- W4311763675 cites W2752700145 @default.
- W4311763675 cites W2758572380 @default.
- W4311763675 cites W2783913006 @default.
- W4311763675 cites W2792190663 @default.
- W4311763675 cites W2792256936 @default.
- W4311763675 cites W2902159880 @default.
- W4311763675 cites W2904873292 @default.
- W4311763675 cites W2969200462 @default.
- W4311763675 cites W2970453706 @default.
- W4311763675 cites W2976761635 @default.
- W4311763675 cites W2980477754 @default.
- W4311763675 cites W2991113088 @default.
- W4311763675 cites W3006121501 @default.
- W4311763675 cites W3115969048 @default.
- W4311763675 cites W3204717935 @default.
- W4311763675 cites W4247665917 @default.
- W4311763675 cites W4255396331 @default.
- W4311763675 doi "https://doi.org/10.1080/14656566.2022.2159373" @default.
- W4311763675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36519357" @default.
- W4311763675 hasPublicationYear "2022" @default.
- W4311763675 type Work @default.
- W4311763675 citedByCount "0" @default.
- W4311763675 crossrefType "journal-article" @default.
- W4311763675 hasAuthorship W4311763675A5005348606 @default.
- W4311763675 hasAuthorship W4311763675A5030480720 @default.
- W4311763675 hasAuthorship W4311763675A5037660224 @default.
- W4311763675 hasAuthorship W4311763675A5058477771 @default.
- W4311763675 hasAuthorship W4311763675A5083862525 @default.
- W4311763675 hasAuthorship W4311763675A5087822441 @default.
- W4311763675 hasConcept C118552586 @default.
- W4311763675 hasConcept C126322002 @default.
- W4311763675 hasConcept C142724271 @default.
- W4311763675 hasConcept C170493617 @default.
- W4311763675 hasConcept C204787440 @default.